MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

Date:

February 8, 2000

To:

Dockets Management Branch (HFA-305)

From:

Melissa Lamb

Office of Generic Drugs

Subject: Project Management in the Office of Generic Drugs

This memorandum forwards overheads of a presentation to the Dockets Management Branch for inclusion in Docket 90S-0308. The following is information on the presentation for the Docket records:

Title of Presentation:

Project Management in the Office of

Generic Drugs

Presented for:

1999 Fall Technical Workshop

Date Presented:

10/18/99

Presented by:

Pat Beers Block

Number of Pages:

19

Attachment

3

0

-

 $\subseteq$ 

871

905-0388

M648

# Project Management in the Office of Generic Drugs

Pat Beers Block, Chief Review Support Branch October 18, 1999

## OGD Project Management: Overview

- History of Project Management
- Objectives
- Staff
- Program Initiatives
- Items to Consider

# **OGD Project Management:** History

- CSOs/Project Managers introduced in early 1990's
- Large volume of work mandated additional staffing
- PMs assigned to Chemistry teams; expanded to include Bioequivalence
   PMs and Microbiology PM
- Chemistry PM = ANDA PM
  - responsible for overall coordination of ANDA review

# OGD Project Management: Objectives

- PMs focus on process and coordination of reviews
- PMs help assure consistency and conformance with OGD policies and procedures
- Facilitate resolution

# OGD Project Management: Tools to Help Meet Objectives

- Master Queue
- Establishment Evaluation System

Team	Project Manager	Therapeutic Categories
Chemistry 1	Bonnie McNeal	Antihypertensive
		Angiotension
		Diuretics
		Radioactive/paques
		NonSteroidal AntiInflammatory
Chemistry 2	Michelle Dillahunt	Estrogens
		Gonadotropins
		Cytotoxic
		Antineoplastic
		Bronchodialator(MDI)
		Surgical-Dental/LVPs

Team	Project Manager	Therapeutic Categories
Chemistry 3	Joe Buccine	AntiAnxiety
		Sedatives
		Dermatologics
		Otics/Opthalmics
		Antifungal/Anti-infectives
Chemistry 4	Ruby Yu	Antipsychotics
	· · · · · · · · · · · · · · · · · · ·	Corticosteroids
		Antihistamine
		Muscle Relaxant
		Contraceptives
		Anabolic Steroids
		Vitamins

Team	Project Manager	Therapeutic Categories
Chemistry 6	Mark Anderson	Antibacterial
		Antifungal*
		Antineoplastic*
		Immuno-suppressants
		* Fermentation Derived
Chemistry 7	Kassandra Sherrod	Anti-Ulcer
		Anticonvulsants
		Antimotility
		Anticholinergics
		Anorexics

Team	Project Manager	Therapeutic Categories
Chemistry 8	Timothy Ames	Beta-blockers
•		Ca-Channel Blockers
		Antiarrhythmics
		Antidepressants
	: 	Drug Abuse Treatment
Chemistry 9	Jeen Min	Antiviral
		Analgesics
		Anesthetics
		Narcotic Agonists
		Anticoagulants

Team	Project Manager	Therapeutic Categories
Microbiology	Joe Buccine	All therapeutic categories
		requiring sterility assurance
		review

- Major/Minor/FAX Program
  - Decrease administrative processing time
  - Prioritize amendments
  - -August 1999 revision

- DMF Faxing Program
  - -Streamlining initiative started in February, 1999
  - Reduces time between reviews and when deficiencies are sent to DMF holder
  - Comments faxed to DMF holder at the same time notice faxed to applicant that DMF deficient

- Automated tracking of 30 Day CBEs
  - Report identifies CBEs requiring GRANT/DENY evaluation
  - Developed in anticipation of FDAMA requirements
- Post Approval Commitment Computer Program
  - Tracks status of post approval commitments
    - e.g.. M.V. samples; dissolution data

- Global Submission Program
  - Started in 1994
  - Encourage firms to submit "global" supplement submission when:
    - identical change affects 5 or more ANDAs with no specific data to be reviewed
  - Adds efficiency to review process
    - one review affects all ANDAs included in global submission
  - Notify Global Coordinator in advance of submitting: Kassandra Sherrod

- Managing Pending Approvals
  - Weekly meetings attended by:
    - Pat Beers Block, Chair
    - Office Director/Deputy Director
    - All Division Directors and Team Leaders
    - Project Managers
    - OGD Special Assist. For Legal Issues
    - Office of Compliance representative
  - Discuss ANDAs potentially eligible for approval

- Address status of all aspects of ANDA review:
  - Applications top priority once chemistry acceptable
  - ANDA PMs serve as spokesperson
- Prepare action items
  - attempt to resolve within one week
  - if ANDA not approved within the week, address at subsequent meeting

#### Items to Consider

- Completeness in Submissions
  - make certain all information provided
  - all deficiencies must be addressed in response
- Clearly identify information on first page of cover letter
  - eg., Minor amendment: chemistry, micro, and labeling deficiencies
  - Global submissions

#### Items to Consider

- Contact appropriate ANDA PM re: submissions
  - Status updates for originals and supplements (except sterility assurance and labeling supplements)
  - Notify ANDA PM of any critical information (eg., T.A. ANDA eligible for full approval because won law suit)
  - Not certain, contact Rev.Sup. Br. Chief

#### Contacts

#### ANDA PMs

- Teams 1-4

301-827-5848

- Teams 6-9

301-827-5849

#### Bioequivalence PMs

**– Teams 1-3** 

301-827-5847

#### Microbiology PM

- Joseph Buccine 301-827-5848